000			02008nam a22003977a 4500
008			210628s20212021 xxu||||| |||| 00| 0 eng d
022			_a0039-6109
024			_a10.1016/j.suc.2021.03.002 [doi]
024			_aS0039-6109(21)00014-1 [pii]
040			_aOvid MEDLINE(R)
099			_a34048760
245			_aAntireflux and Endoscopic Therapies for Barrett Esophagus and Superficial Esophageal Neoplasia. [Review]
251			_aSurgical Clinics of North America. 101(3):391-403, 2021 Jun.
252			_aSurg Clin North Am. 101(3):391-403, 2021 Jun.
253			_aThe Surgical clinics of North America
260			_c2021
260			_fFY2021
260			_p2021 Jun
265			_sppublish
266			_d2021-06-28
501			_aAvailable online from MWHC library: 1996 - present, Available in print through MWHC library: 1999 - February 2007
520			_aBarrett esophagus (BE), defined as intestinal metaplasia of the distal esophageal mucosa, typically results from chronic gastroesophageal reflux disease and is the only known precursor of esophageal adenocarcinoma. The standard of care for the management of early esophageal neoplasia in the setting of BE has changed drastically over the past 15 years. Further investigation into diagnostic and therapeutic adjuncts will continue to improve our ability to control or cure BE before its advancement to a life-threatening malignancy. Copyright (c) 2021 Elsevier Inc. All rights reserved.
546			_aEnglish
650			_aIN PROCESS -- NOT YET INDEXED
651			_aMedStar Franklin Square Medical Center
651			_aMedStar Washington Hospital Center
656			_aGeneral Surgery Residency
656			_aSurgery/General Surgery
657			_aJournal Article
657			_aReview
700			_aFedorova, Ekaterina
700			_aWatson, Thomas J J
790			_aFedorova E, Watson TJ
856			_uhttps://dx.doi.org/10.1016/j.suc.2021.03.002 _zhttps://dx.doi.org/10.1016/j.suc.2021.03.002
942			_cART _dArticle
999			_c6501 _d6501